Accelerate Diagnostics Inc. (NASDAQ:AXDX)’s share price reached a new 52-week high on Tuesday . The stock traded as high as $23.98 and last traded at $23.30, with a volume of 283,400 shares traded. The stock had previously closed at $22.09.

Several equities analysts have recently weighed in on AXDX shares. BTIG Research raised shares of Accelerate Diagnostics from a “neutral” rating to a “buy” rating in a research note on Thursday, August 25th. Zacks Investment Research raised shares of Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research note on Monday, August 29th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $25.00 price target on shares of Accelerate Diagnostics in a research note on Monday, May 16th. Finally, JPMorgan Chase & Co. raised their price target on shares of Accelerate Diagnostics from $17.00 to $25.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 9th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $25.33.

The stock’s market capitalization is $1.20 billion. The stock has a 50 day moving average of $21.14 and a 200-day moving average of $15.46.

In other news, Director Jack W. Schuler acquired 101,272 shares of the company’s stock in a transaction on Thursday, June 9th. The shares were bought at an average cost of $14.14 per share, with a total value of $1,431,986.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Jack W. Schuler acquired 88,316 shares of the company’s stock in a transaction on Friday, June 10th. The stock was purchased at an average cost of $14.69 per share, for a total transaction of $1,297,362.04. The disclosure for this purchase can be found here.

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.